STUDY PHASE I / II DETERMINATION OF THE DOSAGE, PHARMACOKINETICS AND SECURITY OF EPIRUBUBIN (ELLENCE TM / PHARMORRUBICINA TM FARMORRUBICINA TM) IN PEDIATRIC ONCOLOGICAL PATIENTS WITH REFRACTORY OR RECURRENT DISEASE, WITH EVALUATION OF EFFECTIVENESS IN PATIENTS WITH NEUROBLASTOMA, STS AND BONE SARCOMA, REFRACTORY.
Not Applicable
- Registration Number
- PER-106-03
- Lead Sponsor
- PHARMACIA & UPJOHN INTERAMERICAN CORPORATION SUCURSAL DEL PERU,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Be 1 year old or older, but less than 18 years old.
Have a histologically or ecologically documented diagnosis of solid tumor or lymphoma that progressed during one or more previous standard therapies or recurred afterwards, and for which there is no additional standard therapy.
Exclusion Criteria
over 18 years
pregnant women
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method